Table 1.
Patient Demographics.
| Non-Recurrent (N = 25) |
Recurrent (N = 23) |
p-Value * | |
|---|---|---|---|
| Age, years (SD) ** | 59.5 (10.0) | 56.6 (9.0) | 0.30 |
| Gender (%) | 0.10 | ||
| Female | 18 (72) | 21 (91) | |
| Male | 7 (28) | 2 (9) | |
| Ethnicity (%) *** | 0.22 | ||
| African-American | 0 (0) | 2 (9) | |
| Caucasian | 22 (88) | 20 (87) | |
| Hispanic | 3 (12) | 1 (4) | |
| Stage at Diagnosis (%) | 0.36 | ||
| I | 1 (4) | 0 (0) | |
| II | 9 (36) | 5 (22) | |
| III | 15 (60) | 17 (74) | |
| IV | 0 (0) | 1 (4) | |
| HPV status (%) | 10.0 | ||
| Positive | 18 (72) | 18 (78) | |
| Negative | 1 (4) | 1 (4) | |
| Not available | 6 (24) | 4 (17) | |
| HIV Status (%) | 0.46 | ||
| Negative | 25 (100) | 22 (96) | |
| Positive | 0 (0) | 1 (4) | |
| Differentiation (%) | 0.56 | ||
| Well | 1 (4) | 0 (0) | |
| Moderately | 10 (40) | 10 (43) | |
| Poorly | 11 (44) | 13 (57) | |
| Not available | 3 (12) | 0 (0) | |
| Coexisting autoimmune disease (%) | 0.36 | ||
| Absent | 22 (88) | 22 (94) | |
| Present | 3 (12) | 1 (4) | |
| Chemotherapy with radiation | 0.01 | ||
| Fluoropyrimidine + | |||
| mitomycin C | 5 (20) | 13 (57) | |
| Fluoropyrimidine + | |||
| cisplatin | 20 (80) | 10 (4) |
* p-value < 0.05 was considered statistically significant. ** (SD): Standard deviation values for age values inside brackets. *** (%): Percentages values for ethnicity, stage at diagnosis, HPV status, differentiation and coexisting autoimmune disease, inside brackets.